Heng-Cheng Hu

AbbVie (United States)

Papers

2

Total Citations

12

H-Index

2

About

Heng-Cheng Hu is a rising leader in functional genomics, whose work has significantly advanced the power and precision of CRISPR-based screening. His primary research focuses on optimizing genome-wide loss-of-function (LOF) technologies to accelerate the discovery of novel gene functions in both physiological and disease contexts. Hu’s major contribution is the development of enhanced screening platforms using AsCas12a and multi-guide arrays. By addressing key limitations of conventional CRISPR-Cas9 libraries—such as off-target effects and variable cutting efficiency—his optimized method provides a more robust and reliable tool for systematic gene interrogation. This work, detailed in his most-cited 2023 publication (10 citations), has already begun to reshape how researchers design and execute large-scale genetic screens. The impact of his innovations is evident in their potential to streamline the identification of therapeutic targets across diverse biological systems. Through his technical ingenuity, Heng-Cheng Hu is not only refining a cornerstone technology of modern biology but also paving the way for more efficient and accurate discovery in genetics and medicine.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Optimization of Genomewide CRISPR Screens Using AsCas12a and Multi-Guide Arrays
10 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: AbbVie (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago